Psychedelics therapeutics: What we know, what we think, and what we need to research.
David Nutt, Meg J. Spriggs, David Erritzøe
Neuropharmacology September 27, 2022 DOI: 10.1016/j.neuropharm.2022.109257 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Neuroplasticity |
| Keywords | Mental well-being Psychological health Emotional health Behavioral health Brain remodeling Innovative therapies Novel treatments Emerging therapies Advanced treatments Future therapies Breakthrough therapies Paradigm shift New approaches Therapeutic compounds Psychoactive substances Novel compounds Therapeutic substances Mental health tools Psychiatric compounds |
| Citations | 77 |
| Key points | Argues that psychedelic therapy research should be grounded in established facts and current knowledge, and proposes a framework for researchers. |
Abstract
Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge. In this commentary we lay out the knowledge framework that should be taken into account by all innovative researchers in this field.